Indications for and complications of transfusion and the management of gynecologic malignancies

Gynecologic Oncology

Volumn 146, Issue 2, 2017, Pages 416-426

  Cybulska, Paulina ^a   Goss, Cheryl ^a   Tew, William P ^a,b   Parameswaran, Rekha ^a   Sonoda, Yukio ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Anemia; Blood transfusion; Cancer; Gynecologic malignancy

Indexed keywords

ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; IRON; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ANEMIA; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; CHEMOTHERAPY INDUCED ANEMIA; FEMALE; FEMALE GENITAL TRACT CANCER; HUMAN; IMMUNOMODULATION; INFECTION; INFECTION RISK; IRON THERAPY; LABORATORY TEST; OPERATIVE BLOOD LOSS; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RADIATION INJURY; REVIEW; RISK FACTOR; SALVAGE THERAPY; TRANSFUSION RELATED ACUTE LUNG INJURY; TREATMENT INDICATION; ACUTE LUNG INJURY; ADVERSE EFFECTS; BLOOD LOSS, SURGICAL; BLOOD SALVAGE; COMPLICATION; EPIDEMIOLOGY; ERYTHROCYTE TRANSFUSION; GENITAL NEOPLASMS, FEMALE; HEMODILUTION; PERIOPERATIVE PERIOD; PROCEDURES; TRANSFUSION REACTION; TUMOR RECURRENCE;

ACUTE LUNG INJURY; ANEMIA; ANTIFIBRINOLYTIC AGENTS; BLOOD LOSS, SURGICAL; ERYTHROCYTE TRANSFUSION; FEMALE; GENITAL NEOPLASMS, FEMALE; HEMATINICS; HEMODILUTION; HUMANS; IMMUNOMODULATION; INFECTION; IRON; NEOPLASM RECURRENCE, LOCAL; OPERATIVE BLOOD SALVAGE; PERIOPERATIVE CARE; TRANEXAMIC ACID; TRANSFUSION REACTION;

EID: 85019347979     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.05.010     Document Type: Review

References (110)

1. WHO, Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and mineral nutrition information system [internet]. 2011. Available from: http://www.who.int/vmnis/indicators/haemoglobin.pdf, 2011.
2. DR, Basha J., Cable, D., Jones, G., Tranfusions and their costs: managing patients needs and hospitals economics. Internet J. Emerg. Intens. Care Med., 9(2), 2005.
3. Prescott, L.S., Aloia, T.A., Brown, A.J., Taylor, J.S., Munsell, M.F., Sun, C.C., et al. Perioperative blood transfusion in gynecologic oncology surgery: analysis of the National Surgical Quality Improvement Program Database. Gynecol. Oncol. 136:1 (2015), 65–70.
4. Whitaker, B., Rajbhandary, S., Kleinman, S., Harris, A., Kamani, N., Trends in United States blood collection and transfusion: results from the 2013 AABB blood collection, utilization, and patient blood management survey. Transfusion 56:9 (2016), 2173–2183.
5. Watkins, T., Surowiecka, M.K., McCullough, J., Transfusion indications for patients with cancer. Cancer Control 22:1 (2015), 38–46.
6. Carson, J.L., Noveck, H., Berlin, J.A., Gould, S.A., Mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion. J. Gen. Intern. Med., 17, 2002, 111.
7. Henry, D.H., Parenteral iron therapy in cancer-associated anemia. Hematology American Society of Hematology Education Program. 2010, 2010, 351–356.
8. Birgegård, G., Aapro, M.S., Bokemeyer, C., Dicato, M., Drings, P., Hornedo, J., et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 68:Suppl. 1 (2005), 3–11.
9. Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascon, P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 40:15 (2004), 2293–2306.
10. Caro, J.J., Salas, M., Ward, A., Goss, G., Anemia as an independent prognostic factor for survival in patients with cancer - a systematic, quantitative review. Cancer 91:12 (2001), 2214–2221.
11. Knight, K., Wade, S., Balducci, L., Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am. J. Med. 116 (2004), 11–26.
12. Bishop, A.J., Allen, P.K., Klopp, A.H., Meyer, L.A., Eifel, P.J., Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated?. Int. J. Radiat. Oncol. 91:1 (2015), 196–205.
13. Dunst, J., Kuhnt, T., Strauss, H.G., Krause, U., Pelz, T., Koelbl, H., et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int. J. Radiat. Oncol. 56:3 (2003), 778–787.
14. Girinski, T., Pejoviclenfant, M.H., Bourhis, J., Campana, F., Cosset, J.M., Petit, C., et al. Prognostic value of hemoglobin concentrations and blood-transfusions in advanced-carcinoma of the cervix treated by radiation-therapy - results of a retrospective study of 386 patients. Int. J. Radiat. Oncol. 16:1 (1989), 37–42.
15. Grogan, M., Thomas, G.M., Melamed, I., Wong, F.L., Pearcey, R.G., Joseph, P.K., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86:8 (1999), 1528–1536.
16. Haensgen, G., Krause, U., Becker, A., Stadler, P., Lautenschlaeger, C., Wohlrab, W., et al. Tumor hypoxia, p53, and prognosis in cervical cancers. Int. J. Radiat. Oncol. 50:4 (2001), 865–872.
17. Kapp, D.S., Fischer, D., Gutierrez, E., Kohorn, E.I., Schwartz, P.E., Pretreatment prognostic factors in carcinoma of the uterine cervix - a multivariable analysis of the effect of age, stage, histology and blood counts on survival. Int. J. Radiat. Oncol. 9:4 (1983), 445–455.
18. Obermair, A., Cheuk, R., Horwood, K., Janda, M., Bachtiary, B., Schwanzelberger, B., et al. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma - preliminary results. Cancer 92:4 (2001), 903–908.
19. Pedersen, D., Sogaard, H., Overgaard, J., Bentzen, S.M., Prognostic value of pretreatment factors in patients with locally advanced-carcinoma of the uterine cervix treated by radiotherapy alone. Acta Oncol. 34:6 (1995), 787–795.
20. Thomas, G., The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin. Oncol. 28:2 (2001), 60–65.
21. Wernerwasik, M., Schmid, C.H., Bornstein, L., Ball, H.G., Smith, D.M., Madocjones, H., Prognostic factors for local and distant recurrence in stage-I and stage-ii cervical-carcinoma. Int. J. Radiat. Oncol. 32:5 (1995), 1309–1317.
22. Yalman, D., Aras, A.B., Ozkok, S., Duransoy, A., Celik, O.K., Ozsaran, Z., et al. Prognostic factors in definitive radiotherapy of uterine cervical cancer. Eur. J. Gynaecol. Oncol. 24:3–4 (2003), 309–314.
23. Winter, W.E., Maxwell, G.L., Tian, C.Q., Sobel, E., Rose, G.S., Thomas, G., et al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a gynecologic oncology group study. Gynecol. Oncol. 94:2 (2004), 495–501.
24. Fuso, L., Mazzola, S., Marocco, F., Ferrero, A., Dompe, D., Carus, A.P., et al. Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: a preliminary report. Gynecol. Oncol. 99:3 Suppl 1 (2005), S187–S191.
25. Grigiene, R., Valuckas, K.P., Aleknavicius, E., Kurtinaitis, J., Letautiene, S.R., The value of prognostic factors for uterine cervical cancer patients treated with irradiation alone. BMC Cancer, 234, 2007.
26. Mayr, N.A., Wang, J.Z., Zhang, D.Q., Montebello, J.F., Grecula, J.C., Lo, S.S., et al. Synergistic effects of hemoglobin and tumor perfusion on tumor control and survival in cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 74:5 (2009), 1513–1521.
27. Endo, D., Todo, Y., Okamoto, K., Minobe, S., Kato, H., Nishiyama, N., Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort. J. Gynecol. Oncol. 26:1 (2015), 12–18.
28. Shin, N.R., Lee, Y.Y., Kim, S.H., Choi, C.H., Kim, T.J., Lee, J.W., et al. Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer. Obstet. Gynecol. Sci. 57:1 (2014), 28–36.
29. Metindir, J., Dilek, G.B., Preoperative hemoglobin and platelet count and poor prognostic factors in patients with endometrial carcinoma. J. Cancer Res. Clin. 135:1 (2009), 125–129.
30. Njolstad, T.S., Engerud, H., Werner, H.M.J., Salvesen, H.B., Trovik, J., Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas. Gynecol. Oncol. 131:2 (2013), 410–415.
31. Wilairat, W., Benjapibal, M., Presence of anemia and poor prognostic factors in patients with endometrial carcinoma. Asian Pac. J. Cancer Prev. 13:7 (2012), 3187–3190.
32. Munstedt, K., Kovacic, M., Zygmunt, M., von Georgi, R., Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int. J. Oncol. 23:3 (2003), 837–843.
33. Maccio, A., Madeddu, C., Massa, D., Mudu, M.C., Lusso, M.R., Gramignano, G., et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 106:1 (2005), 362–367.
34. Obermair, A., Handisurya, A., Kaider, A., Sevelda, P., Kölbl, H., Gitsch, G., The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients. Cancer 83:4 (1998), 726–731.
35. Warner, L.L., Dowdy, S.C., Martin, J.R., Lemens, M.A., McGree, M.E., Weaver, A.L., et al. The impact of perioperative packed red blood cell transfusion on survival in epithelial ovarian cancer. Int. J. Gynecol. Cancer 23:9 (2013), 1612–1619.
36. Safra, T., Muggia, F., Jeffers, S., Tsao-Wei, D.D., Groshen, S., Lyass, O., et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m(2). Ann. Oncol. 11:8 (2000), 1029–1033.
37. Eichbaum, M.H.R., Weiss, L.M.E., Bruckner, T., Schneeweiss, A., Sinn, H.P., Gebauer, G., et al. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. Med. Sci. Monit., 15(4), 2009, Cr156-Cr63.
38. Hefler, L., Mayerhofer, K., Leibman, B., Obermair, A., Reinthaller, A., Kainz, C., et al. Tumor anemia and thrombocytosis in patients with vulvar cancer. Tumor Biol. 21:5 (2000), 309–314.
39. Dicato, M., Plawny, L., Diederich, M., Anemia in cancer. Ann. Oncol. 21 (2010), 167–172.
40. Groopman, J.E., Itri, L.M., Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl. Cancer Inst. 91:19 (1999), 1616–1634.
41. Kumagai, S., Sugiyama, T., Shoji, T., Michimae, H., Katsumata, N., Aoki, D., et al. Does severe anemia caused by dose-dense paclitaxel-carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial. Int. J. Gynecol. Cancer 21:9 (2011), 1585–1591.
42. Hensley, M.L., Lebeau, D., Leon, L., Venkatraman, E., Waltzman, R., Sabbatini, P., et al. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Gynecol. Oncol. 81:3 (2001), 485–489.
43. Barrett-Lee, P., Bailey, N., O'Brien, M., Wager, E., Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br. J. Cancer, 82(1), 2000, 93.
44. Stüben, G., Thews, O., Pöttgen, C., Knühmann, K., Vaupel, P., Stuschke, M., Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J. Cancer Res. Clin. Oncol. 127:6 (2001), 346–350.
45. Klopp, A.H., Eifel, P.J., (eds.) Biological predictors of cervical cancer response to radiation therapy, Seminars in Radiation Oncology, 2012, Elsevier.
46. Kapp, K.S., Poschauko, J., Geyer, E., Berghold, A., Oechs, A.C., Petru, E., et al. Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. Int. J. Radiat. Oncol. 54:1 (2002), 58–66.
47. Bush, R.S., The significance of anemia in clinical radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 12:11 (1986), 2047–2050.
48. Rodgers, G.M. 3rd, Becker, P.S., Blinder, M., Cella, D., Chanan-Khan, A., Cleeland, C., et al. Cancer- and chemotherapy-induced anemia. J. Natl. Compr. Cancer Netw. 10:5 (2012), 628–653.
49. Carson, J.L., Guyatt, G., Heddle, N.M., Grossman, B.J., Cohn, C.S., Fung, M.K., et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA, 2016.
50. Stehling, L.C., Doherty, D.C., Faust, R.J., Greenburg, A.G., Harrison, C.R., Landers, D.F., et al. Practice guidelines for blood component therapy - a report by the American Society of Anesthesiologists Task Force on blood component therapy. Anesthesiology 84:3 (1996), 732–747.
51. Hebert, P.C., Wells, G., Blajchman, M.A., Marshall, J., Martin, C., Pagliarello, G., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care (vol 340, pg 409, 1999). N. Engl. J. Med., 340(13), 1999, 1056.
52. Hajjar, L.A., Vincent, J.L., Galas, F.R.B.G., Nakamura, R.E., Silva, C.M.P., Santos, M.H., et al. Transfusion requirements after cardiac surgery the TRACS randomized controlled trial. JAMA 304:14 (2010), 1559–1567.
53. Corwin, H.L., Gettinger, A., Pearl, R.G., Fink, M.P., Levy, M.M., Abraham, E., et al. The CRIT study: anemia and blood transfusion in the critically ill - current clinical practice in the United States. Crit. Care Med. 32:1 (2004), 39–52.
54. Carson, J.L., Rhoads, G.G., Magaziner, J., Transfusion thresholds in high-risk patients after hip surgery REPLY. N. Engl. J. Med. 366:13 (2012), 1254–1255.
55. Holst, L.B., Haase, N., Wetterslev, J., Wernerman, J., Guttormsen, A.B., Karlsson, S., et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N. Engl. J. Med. 371:15 (2014), 1381–1391.
56. Carson, J.L., Carless, P.A., Hebert, P.C., Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Db. Syst. Rev., 4, 2012.
57. de Almeida, J.P., Vincent, J.L., Galas, F.R.B.G., de Almeida, E.P.M., Fukushima, J.T., Osawa, E.A., et al. Transfusion requirements in surgical oncology patients a prospective, randomized controlled trial. Anesthesiology 122:1 (2015), 29–38.
58. Boone, J.D., Kim, K.H., Marques, M., Straughn, J.M., Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients. Gynecol. Oncol. 132:1 (2014), 227–230.
59. Price, F.V., Kelley, J.L., Edwards, R.P., Hasley, P.B., Amin, R.M., A survey of blood-transfusion practices of gynecologic oncologists. Gynecol. Oncol. 59:1 (1995), 45–50.
60. Delaney, M., Wendel, S., Bercovitz, R.S., Cid, J., Cohn, C., Dunbar, N.M., et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet 388:10061 (2016), 2825–2836.
61. Kleinman, S., Caulfield, T., Chan, P., Davenport, R., McFarland, I., McPhedran, S., et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 44:12 (2004), 1774–1789.
62. Edgren, G., Kamper-Jorgensen, M., Eloranta, S., Rostgaard, K., Custer, B., Ullum, H., et al. Duration of red blood cell storage and survival of transfused patients (CME). Transfusion 50:6 (2010), 1185–1195.
63. Andrzejewski, C., Casey, M.A., Popovsky, M.A., How we view and approach transfusion-associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention. Transfusion 53:12 (2013), 3037–3047.
64. Opelz, G., Immunological reactivity of transplant recipients. Lancet 1:7799 (1973), 373–374.
65. Gantt, C.L., Red-blood-cells for cancer-patients. Lancet, 2(8242), 1981, 363.
66. Cata, J.P., Wang, H., Gottumukkala, V., Reuben, J., Sessler, D.I., Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br. J. Anaesth. 110:5 (2013), 690–701.
67. Benson, D., Barnett, C.C. Jr., Perioperative blood transfusions promote pancreas cancer progression. J. Surg. Res. 166:2 (2011), 275–279.
68. Acheson, A.G., Brookes, M.J., Spahn, D.R., Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery a systematic review and meta-analysis. Ann. Surg. 256:2 (2012), 235–244.
69. De Oliveira, G.S., Schink, J.C., Buoy, C., Ahmad, S., Fitzgerald, P.C., McCarthy, R.J., The association between allogeneic perioperative blood transfusion on tumour recurrence and survival in patients with advanced ovarian cancer. Transfus. Med. 22:2 (2012), 97–103.
70. Azuma, C., Koyama, M., Inagaki, M., Ito, S., Sawada, M., Saji, F., et al. The influence of peri-operative blood transfusion during radical hysterectomy on the prognosis of uterine cervical cancer. Transfus. Sci. 18:1 (1997), 55–62.
71. Monk, B.J., Tewari, K., Gamboavujicic, G., Burger, R.A., Manetta, A., Berman, M.L., Does perioperative blood-transfusion affect survival in patients with cervical-cancer treated with radical hysterectomy. Obstet. Gynecol. 85:3 (1995), 343–348.
72. Rohde, J.M., Health care-associated infection after red blood cell transfusion: a systematic review and metaanalysis (vol 311, pg 1317, 2014). JAMA, 312(19), 2014, 2045.
73. Bernard, A.C., Davenport, D.L., Chang, P.K., Vaughan, T.B., Zwschenberger, J.B., Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. J. Am. Coll. Surg. 208:5 (2009), 931–937.
74. Abu-Rustum, N.R., Richard, S., Wilton, A., Lev, G., Sonoda, Y., Hensley, M.L., et al. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival. Gynecol. Oncol. 99:2 (2005), 320–326.
75. Devine, D.V., Schubert, P., Pathogen inactivation technologies the advent of pathogen-reduced blood components to reduce blood safety risk. Hematol. Oncol. Clin. North Am., 30(3), 2016, 609.
76. Devine, D.V., Schubert, P., Pathogen inactivation technologies: the advent of pathogen-reduced blood components to reduce blood safety risk. Hematol. Oncol. Clin. North Am. 30:3 (2016), 609–617.
77. Aubry, M., Richard, V., Green, J., Broult, J., Musso, D., Inactivation of Zika virus in plasma with amotosalen and ultraviolet a illumination. Transfusion 56:1 (2016), 33–40.
78. Knutson, F., Osselaer, J., Pierelli, L., Lozano, M., Cid, J., Tardivel, R., et al. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang. 109:4 (2015), 343–352.
79. Osselaer, J.C., Messe, N., Hervig, T., Bueno, J., Castro, E., Espinosa, A., et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 48:6 (2008), 1061–1071.
80. Kleinman, S., Stassinopoulos, A., Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation. Transfusion 55:12 (2015), 2983–3000.
81. Athibovonsuk, P., Manchana, T., Sirisabya, N., Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol. Oncol. 131:3 (2013), 679–682.
82. Dangsuwan, P., Manchana, T., Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol. Oncol. 116:3 (2010), 522–525.
83. Kim, Y.T., Kim, S.W., Yoon, B.S., Cho, H.J., Nahm, E.J., Kim, S.H., et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol. Oncol. 105:1 (2007), 199–204.
84. Bastit, L., Vandebroek, A., Altintas, S., Gaede, B., Pinter, T., Suto, T.S., et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J. Clin. Oncol. 26:10 (2008), 1611–1618.
85. Sabbatini, P., Contibution of anemia to fatigue in the cancer patient. Oncology (Williston Park) 14:11A (2000), 69–71.
86. Sabbatini, P., The relationship between anemia and quality of life in cancer patients. Oncologist 5:Suppl. 2 (2000), 19–23.
87. Rizzo, J.D., Somerfield, M.R., Hagerty, K.L., Seidenfeld, J., Bohlius, J., Bennett, C.L., et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 111:1 (2008), 25–41.
88. Auerbach, M., Ballard, H., Trout, J.R., McIlwain, M., Ackerman, A., Bahrain, H., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 22:7 (2004), 1301–1307.
89. Dousias, V., Stefos, T., Navrozoglou, I., Staikos, I., Ditto, A., Paraskevaidis, E., Administration of recombinant human erythropoietin in patients with gynecological cancer before radical surgery. Clin. Exp. Obstet. Gynecol. 32:2 (2005), 129–131.
90. Wilkinson, P.M., Antonopoulos, M., Lahousen, M., Lind, M., Kosmidis, P., Group E-I-S, Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br. J. Cancer 94:7 (2006), 947–954.
91. Huinink, W.W.T., de Swart, C.A.M., van Toorn, D.W., Morack, G., Breed, W.P.M., Hillen, H.F.P., et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med. Oncol. 15:3 (1998), 174–182.
92. Leyland-Jones, B., Bondarenko, I., Nemsadze, G., Smirnov, V., Litvin, I., Kokhreidze, I., A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy. J. Clin. Oncol. 34:11 (2016), 1197–1207.
93. Lippi, G., Franchini, M., Favaloro, E.J., Thrombotic complications of erythropoiesis-stimulating agents. Semin. Thromb. Hemost. 36:5 (2010), 537–549.
94. Hedley, B.D., Allan, A.L., Xenocostas, A., The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin. Cancer Res. 17:20 (2011), 6373–6380.
95. Glaspy, J., Update on safety of ESAs in cancer-induced anemia. J. Natl. Compr. Cancer Netw. 10:5 (2012), 659–666.
96. Lavey, R.S., Liu, P.Y., Greer, B.E., Robinson, W.R., Chang, P.C., Wynn, R.B., et al. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a southwest oncology group study. Gynecol. Oncol. 95:1 (2004), 145–151.
97. Thomas, G., Ali, S., Hoebers, F.J., Darcy, K.M., Rodgers, W.H., Patel, M., et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol. Oncol. 108:2 (2008), 317–325.
98. Blohmer, J.U., Paepke, S., Sehouli, J., Boehmer, D., Kolben, M., Wurschmidt, F., et al. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J. Clin. Oncol. 29:28 (2011), 3791–3797.
99. Barile, L., Fominskiy, E., Di Tomasso, N., Castro, L.E.A., Landoni, G., De Luca, M., et al. Acute normovolemic hemodilution reduces allogeneic red blood cell transfusion in cardiac surgery: a systematic review and meta-analysis of randomized trials. Anesth. Analg. 124:3 (2017), 743–752.
100. Zulim, R.A., Rocco, M., Goodnight, J.E., Smith, G.J., Krag, D.N., Schneider, P.D., Intraoperative autotransfusion in hepatic resection for malignancy. Is it safe?. Arch. Surg. 128:2 (1993), 206–211.
101. Mirhashemi, R., Averette, H.E., Deepika, K., Estape, R., Angioli, R., Martin, J., The impact of intraoperative autologous blood transfusion during type III radical hysterectomy for early-stage cervical cancer. Am. J. Obstet. Gynecol. 181:6 (1998), 1310–1315 (discussion 5–6).
102. Connor, J.P., Morris, P.C., Alagoz, T., Anderson, B., Bottles, K., Buller, R.E., Intraoperative autologous blood collection and autotransfusion in the surgical management of early cancers of the uterine cervix. Obstet. Gynecol. 86:3 (1995), 373–378.
103. Engle, D.B., Connor, J.P., Morris, P.C., Bender, D.P., De Geest, K., Ahmed, A., et al. Intraoperative autologous blood transfusion use during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trial. Arch. Gynecol. Obstet. 286:3 (2012), 717–721.
104. Cata, J.P., Wang, H., Gottumukkala, V., Reuben, J., Sessler, D.I., Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br. J. Anaesth. 110:5 (2013), 690–701.
105. Crescenti, A., Borghi, G., Bignami, E., Bertarelli, G., Landoni, G., Casiraghi, G.M., et al. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial. BMJ, 343, 2011, d5701.
106. Lundin, E.S., Johansson, T., Zachrisson, H., Leandersson, U., Backman, F., Falknas, L., et al. Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study. Acta Obstet. Gynecol. Scand. 93:4 (2014), 335–344.
107. Meybohm, P., Richards, T., Isbister, J., Hofmann, A., Shander, A., Goodnough, L.T., et al. Patient blood management bundles to facilitate implementation. Transfus. Med. Rev. 31:1 (2017), 62–71.
108. Kaufman, R.M., Djulbegovic, B., Gernsheimer, T., Kleinman, S., Tinmouth, A.T., Capocelli, K.E., et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann. Intern. Med. 162:3 (2015), 205–213.
109. Wilkes, M.M., Navickis, R.J., Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann. Intern. Med. 135:3 (2001), 149–164.
110. Trakarnsanga, K., Griffiths, R.E., Wilson, M.C., Blair, A., Satchwell, T.J., Meinders, M., et al. An immortalized adult human erythroid line facilitates sustainable and scalable generation of functional red cells. Nat. Commun., 8, 2017, 14750.